NASDAQ:HCM 延时15分钟

成交量

Chig Fung Cheng: Chig Fung Cheng currently works at HUTCHMED (China) Ltd., as CEO, Chief Financial Officer & Executive Director from 2025, Hutchison MediPharma Ltd., as Director, Sen Medicine Co. Ltd., as Director, Hutchison Medipharma (Hong Kong) Ltd., as Director, Hutchison Medipharma (Suzhou) Ltd., as Director, The Institute of Chartered Accountants in Australia, as Member, and Chartered Accountants Australia & New Zealand, as Member. Mr. Cheng also formerly worked at Hutchison Healthcare Ltd., as Director, Bristol-Myers Squibb (China) Investment Co. Ltd., as Director from 2006 to 2008, Sino-American Shanghai Squibb Pharmaceuticals Ltd., as Director, PricewaterhouseCoopers (Australia), as Auditor, Bristol-Myers Squibb (China) Pharmaceuticals Co. Ltd., as Vice President-Finance, Nestl (China) Ltd., as Controller, and KPMG Beijing, as Auditor. Mr. Cheng received his undergraduate degree from the University of Adelaide.; 旧服务已下线，请迁移至 http://api.fanyi.baidu.com

Wei Guo Su: Wei Guo Su currently works at HUTCHMED (China) Ltd., as Executive Director & Chief Scientific Officer from 2025, ImageneBio, Inc., as Independent Director from 2025, and Hutchison MediPharma Ltd., as Chief Scientific Officer & Executive VP from 2012. Dr. Su also formerly worked at Pfizer Inc., as Director-Medicinal Chemistry Department. Dr. Su received his doctorate degree from Harvard University and undergraduate degree from Fudan University.

Edith Shih: Edith Shih currently works at The Hong Kong University of Science & Technology, as Vice Chairman-Council, Accounting & Financial Reporting Council, as Chairman-Process Review Panel, Maritime Transport Services Ltd., as Director, and various other companies. Ms. Shih also formerly worked at China Oceanwide Holdings Ltd., as Secretary & Executive Director from 2012 to 2014, VC Capital Ltd., as Director from 1989 to 1991, H3G SpA, as Director, and various other companies. Ms. Shih received her graduate degree from The Trustees of Columbia University in The City of New York and undergraduate degree and graduate degree from the University of the Philippines.; 旧服务已下线，请迁移至 http://api.fanyi.baidu.com

Michael Leung: Michael Leung currently works at HUTCHMED (China) Ltd., as Vice President-Corporate Operations. Mr. Leung received his Masters Business Admin degree from the University of British Columbia and undergraduate degree from Simon Fraser University.

Chig Fung Cheng: Chig Fung Cheng currently works at HUTCHMED (China) Ltd., as CEO, Chief Financial Officer & Executive Director from 2025, Hutchison MediPharma Ltd., as Director, Sen Medicine Co. Ltd., as Director, Hutchison Medipharma (Hong Kong) Ltd., as Director, Hutchison Medipharma (Suzhou) Ltd., as Director, The Institute of Chartered Accountants in Australia, as Member, and Chartered Accountants Australia & New Zealand, as Member. Mr. Cheng also formerly worked at Hutchison Healthcare Ltd., as Director, Bristol-Myers Squibb (China) Investment Co. Ltd., as Director from 2006 to 2008, Sino-American Shanghai Squibb Pharmaceuticals Ltd., as Director, PricewaterhouseCoopers (Australia), as Auditor, Bristol-Myers Squibb (China) Pharmaceuticals Co. Ltd., as Vice President-Finance, Nestl (China) Ltd., as Controller, and KPMG Beijing, as Auditor. Mr. Cheng received his undergraduate degree from the University of Adelaide.; 旧服务已下线，请迁移至 http://api.fanyi.baidu.com

Wei Guo Su: Wei Guo Su currently works at HUTCHMED (China) Ltd., as Executive Director & Chief Scientific Officer from 2025, ImageneBio, Inc., as Independent Director from 2025, and Hutchison MediPharma Ltd., as Chief Scientific Officer & Executive VP from 2012. Dr. Su also formerly worked at Pfizer Inc., as Director-Medicinal Chemistry Department. Dr. Su received his doctorate degree from Harvard University and undergraduate degree from Fudan University.

Qing Mei Wang: Qing Mei Wang currently works at HUTCHMED (China) Ltd., as SVP-Business Development & Strategic Alliances from 2010 and Hutchison MediPharma Ltd., as SVP-Business Development & Strategic Alliances from 2012. Dr. Wang also formerly worked at Eli Lilly & Co., as Head-Asia Discovery Biology. Dr. Wang received her doctorate degree from Purdue University.

Charles Nixon: Charles Nixon is currently the Group General Counsel at HUTCHMED (China) Ltd. He previously worked as Group Senior Legal Counsel at Hutchison Whampoa Ltd., Group Senior Legal Counsel at Hutchison Whampoa Services Ltd., and Senior Legal Counsel at Hutchison 3G UK Ltd. He is a graduate of Middlesex University.; 旧服务已下线，请迁移至 http://api.fanyi.baidu.com

Mark Lee: Mark Lee currently works at HUTCHMED (China) Ltd., as SVP-Corporate Management & Communications. Mr. Lee received his undergraduate degree from University College London and Masters Business Admin degree from MIT Sloan School of Management.

Yiling Cui: Yiling Cui currently works at HUTCHMED (China) Ltd., as Executive Vice President & Head-Operations. Ms. Cui also formerly worked at Shanghai Asia Pioneer Pharmaceuticals Co. Ltd., as Chief Executive Officer, Sino-American Shanghai Squibb Pharmaceuticals Ltd., as Chairman, Shanghai New Asiatic Pharmaceuticals Co., Ltd., as Chairman, and Shanghai Shyndec Pharmaceutical Co., Ltd., as Vice President. Ms. Cui received her Masters Business Admin degree in 2003 from China Europe International Business School and undergraduate degree in 1987 from Fudan University.

Karen Atkin: Karen Atkin currently works at HUTCHMED (China) Ltd., as Chief Operating Officer & Executive Vice President from 2021 and The Royal College of Physicians, as Member. Dr. Atkin also formerly worked at AstraZeneca PLC, as Country President-Indonesia. Dr. Atkin received her undergraduate degree from University College London and Masters Business Admin degree and doctorate degree from Open University of China.

Selina Zhang: Selina Zhang currently works at HUTCHMED (China) Ltd., as Senior Vice President-Global Human Resources from 2022. Ms. Zhang received her Masters Business Admin degree from International Institute for Management Development and graduate degree from Capital University of Economics & Business.

Ming Shi: Ming Shi currently works at American Society of Clinical Oncology, Inc., as Member, American Association for Cancer Research, as Member, American Society of Hematology, as Member, European Society for Medical Oncology, as Member, Sino-American Pharmaceutical Professionals Association, as Member, and HUTCHMED (China) Ltd., as Chief Medical Officer, EVP, Head-R&D from 2022. Dr. Shi also formerly worked at National Institutes of Health, as Program Director-Genetics Variation, the University of Michigan Medical School, as Adjunct Assistant Professor, and Transcenta Holding Ltd., as Chief Medical Officer, Head-R&D. Dr. Shi received his doctorate degree from the University of Southern California.

Hong Chen: Hong Chen is currently the General Manager at Hutchison Healthcare Ltd., the General Manager at Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Co., and the Chief Commercial Officer & Executive VP at HUTCHMED (China) Ltd. Mr. Chen has an MBA from Cheung Kong Graduate School of Business and an undergraduate degree from Nanjing Medical University.

David Ng: David Ng currently works at HUTCHMED (China) Ltd., as Vice President-Investor Relations from 2023. Mr. Ng also formerly worked at Macquarie Capital Ltd., as Analyst from 2011 to 2021, ABN AMRO Asia Ltd., as Research Analyst, UBS Securities (Asia) Ltd., as Research Analyst, and Credit Agricole Securities (Asia) Ltd, as Research Analyst from 2009 to 2011.

和黄药业